The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias
Acute leukemia is the most common type of childhood and adolescence cancer, characterized by clonal proliferation of variably differentiated myeloid or lymphoid precursors. Recent insights into the molecular pathogenesis of leukemia have shown that epigenetic modifications, such as deacetylation of...
Gespeichert in:
| Veröffentlicht in: | BioMed research international 2011-01, Vol.2011 (2011), p.1-9 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 9 |
|---|---|
| container_issue | 2011 |
| container_start_page | 1 |
| container_title | BioMed research international |
| container_volume | 2011 |
| creator | Pession, Andrea Biagi, Carlotta Serravalle, Salvatore Masetti, Riccardo |
| description | Acute leukemia is the most common type of childhood and adolescence cancer, characterized by clonal proliferation of variably differentiated myeloid or lymphoid precursors. Recent insights into the molecular pathogenesis of leukemia have shown that epigenetic modifications, such as deacetylation of histones and DNA methylation, play crucial roles in leukemogenesis, by transcriptional silencing of critical genes. Histone deacetylases (HDACs) are potential targets in the treatment of leukaemia, and, as a consequence, inhibitors of HDACs (HDIs) are being studied for therapeutic purposes. HDIs promote or enhance several different anticancer mechanisms, such as apoptosis, cell cycle arrest, and cellular differentiation and, therefore, are in evidence as promising treatment for children and adolescents with acute leukemia, in monotherapy or in association with other anticancer drugs. Here we review the main preclinical and clinical studies regarding the use of HDIs in treating childhood and adolescence leukemia. |
| doi_str_mv | 10.1155/2011/148046 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3026992</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A266629939</galeid><sourcerecordid>A266629939</sourcerecordid><originalsourceid>FETCH-LOGICAL-e454t-b36f061b7976fb646a3e91370e2559b53959b20b19dea7726f7775eb45208953</originalsourceid><addsrcrecordid>eNpt0l2L1DAUBuAgiruuXnmtBL0QhO7mJE3S3Ahl_NiBAUHmPqTt6TRrJ1n7oey_3wxdB1eGQlrSJ2-T00PIa2CXAFJecQZwBXnBcvWEnAMAyzSX8PT4nIsz8mIcbxgDXSjznJxxEFCAKs7Jetsh_RF7pLGl15_L1UjXofOVn-IwUh_oqvN908XYUBcaWjaJjjWGGmlZzxPSDc4_ce_d-JI8a10_4quH-wXZfv2yXV1nm-_f1qtyk2Eu8ymrhGqZgkobrdpK5coJNCA0Qy6lqaQwaeSsAtOg05qrVmstscolZ4WR4oJ8WmJv52qPTdrKNLje3g5-74Y7G523j98E39ld_G0F48oYngI-PAQM8deM42T3Pp2o713AOI-2kKAlKxhL8t1_8ibOQ0iHS0iB1kof4t4vaOd6tD60MX21PkTakiuluDHCJJWdUDsMmLYYA7Y-TT_ylyd8uppU6_rkgrf_luVYj79_OoGPC-h8aNwffxTA7KGN7KGN7NJGCb9ZMCaCrTviPDdSKXEPenq8JA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>856177672</pqid></control><display><type>article</type><title>The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Pession, Andrea ; Biagi, Carlotta ; Serravalle, Salvatore ; Masetti, Riccardo</creator><contributor>Seiser, Christian</contributor><creatorcontrib>Pession, Andrea ; Biagi, Carlotta ; Serravalle, Salvatore ; Masetti, Riccardo ; Seiser, Christian</creatorcontrib><description>Acute leukemia is the most common type of childhood and adolescence cancer, characterized by clonal proliferation of variably differentiated myeloid or lymphoid precursors. Recent insights into the molecular pathogenesis of leukemia have shown that epigenetic modifications, such as deacetylation of histones and DNA methylation, play crucial roles in leukemogenesis, by transcriptional silencing of critical genes. Histone deacetylases (HDACs) are potential targets in the treatment of leukaemia, and, as a consequence, inhibitors of HDACs (HDIs) are being studied for therapeutic purposes. HDIs promote or enhance several different anticancer mechanisms, such as apoptosis, cell cycle arrest, and cellular differentiation and, therefore, are in evidence as promising treatment for children and adolescents with acute leukemia, in monotherapy or in association with other anticancer drugs. Here we review the main preclinical and clinical studies regarding the use of HDIs in treating childhood and adolescence leukemia.</description><identifier>ISSN: 1110-7243</identifier><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 1110-7251</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2011/148046</identifier><identifier>PMID: 21318168</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Puplishing Corporation</publisher><subject>Adolescent ; Animals ; Antimitotic agents ; Antineoplastic agents ; Apoptosis ; Cancer ; Chemotherapy ; Child ; Clinical Trials as Topic ; Cyclin-dependent kinases ; DNA ; DNA methylation ; Drug Evaluation, Preclinical ; Drug therapy ; Epigenetics ; Health aspects ; Histone Deacetylase Inhibitors - chemistry ; Histone Deacetylase Inhibitors - therapeutic use ; Histone Deacetylases - metabolism ; Humans ; Leukemia ; Leukemia - drug therapy ; Leukemia - enzymology ; Methylation ; Physiological aspects ; Review ; Risk assessment ; Rodents ; Studies ; Tumors</subject><ispartof>BioMed research international, 2011-01, Vol.2011 (2011), p.1-9</ispartof><rights>Copyright © 2011 Riccardo Masetti et al.</rights><rights>COPYRIGHT 2011 John Wiley & Sons, Inc.</rights><rights>Copyright © 2011 Riccardo Masetti et al. Riccardo Masetti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2011 Riccardo Masetti et al. 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3026992/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3026992/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21318168$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Seiser, Christian</contributor><creatorcontrib>Pession, Andrea</creatorcontrib><creatorcontrib>Biagi, Carlotta</creatorcontrib><creatorcontrib>Serravalle, Salvatore</creatorcontrib><creatorcontrib>Masetti, Riccardo</creatorcontrib><title>The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias</title><title>BioMed research international</title><addtitle>J Biomed Biotechnol</addtitle><description>Acute leukemia is the most common type of childhood and adolescence cancer, characterized by clonal proliferation of variably differentiated myeloid or lymphoid precursors. Recent insights into the molecular pathogenesis of leukemia have shown that epigenetic modifications, such as deacetylation of histones and DNA methylation, play crucial roles in leukemogenesis, by transcriptional silencing of critical genes. Histone deacetylases (HDACs) are potential targets in the treatment of leukaemia, and, as a consequence, inhibitors of HDACs (HDIs) are being studied for therapeutic purposes. HDIs promote or enhance several different anticancer mechanisms, such as apoptosis, cell cycle arrest, and cellular differentiation and, therefore, are in evidence as promising treatment for children and adolescents with acute leukemia, in monotherapy or in association with other anticancer drugs. Here we review the main preclinical and clinical studies regarding the use of HDIs in treating childhood and adolescence leukemia.</description><subject>Adolescent</subject><subject>Animals</subject><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Apoptosis</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Clinical Trials as Topic</subject><subject>Cyclin-dependent kinases</subject><subject>DNA</subject><subject>DNA methylation</subject><subject>Drug Evaluation, Preclinical</subject><subject>Drug therapy</subject><subject>Epigenetics</subject><subject>Health aspects</subject><subject>Histone Deacetylase Inhibitors - chemistry</subject><subject>Histone Deacetylase Inhibitors - therapeutic use</subject><subject>Histone Deacetylases - metabolism</subject><subject>Humans</subject><subject>Leukemia</subject><subject>Leukemia - drug therapy</subject><subject>Leukemia - enzymology</subject><subject>Methylation</subject><subject>Physiological aspects</subject><subject>Review</subject><subject>Risk assessment</subject><subject>Rodents</subject><subject>Studies</subject><subject>Tumors</subject><issn>1110-7243</issn><issn>2314-6133</issn><issn>1110-7251</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpt0l2L1DAUBuAgiruuXnmtBL0QhO7mJE3S3Ahl_NiBAUHmPqTt6TRrJ1n7oey_3wxdB1eGQlrSJ2-T00PIa2CXAFJecQZwBXnBcvWEnAMAyzSX8PT4nIsz8mIcbxgDXSjznJxxEFCAKs7Jetsh_RF7pLGl15_L1UjXofOVn-IwUh_oqvN908XYUBcaWjaJjjWGGmlZzxPSDc4_ce_d-JI8a10_4quH-wXZfv2yXV1nm-_f1qtyk2Eu8ymrhGqZgkobrdpK5coJNCA0Qy6lqaQwaeSsAtOg05qrVmstscolZ4WR4oJ8WmJv52qPTdrKNLje3g5-74Y7G523j98E39ld_G0F48oYngI-PAQM8deM42T3Pp2o713AOI-2kKAlKxhL8t1_8ibOQ0iHS0iB1kof4t4vaOd6tD60MX21PkTakiuluDHCJJWdUDsMmLYYA7Y-TT_ylyd8uppU6_rkgrf_luVYj79_OoGPC-h8aNwffxTA7KGN7KGN7NJGCb9ZMCaCrTviPDdSKXEPenq8JA</recordid><startdate>20110101</startdate><enddate>20110101</enddate><creator>Pession, Andrea</creator><creator>Biagi, Carlotta</creator><creator>Serravalle, Salvatore</creator><creator>Masetti, Riccardo</creator><general>Hindawi Puplishing Corporation</general><general>Hindawi Publishing Corporation</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>ACNOP</scope><scope>ADJCN</scope><scope>AEEDL</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20110101</creationdate><title>The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias</title><author>Pession, Andrea ; Biagi, Carlotta ; Serravalle, Salvatore ; Masetti, Riccardo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e454t-b36f061b7976fb646a3e91370e2559b53959b20b19dea7726f7775eb45208953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Animals</topic><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Apoptosis</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Clinical Trials as Topic</topic><topic>Cyclin-dependent kinases</topic><topic>DNA</topic><topic>DNA methylation</topic><topic>Drug Evaluation, Preclinical</topic><topic>Drug therapy</topic><topic>Epigenetics</topic><topic>Health aspects</topic><topic>Histone Deacetylase Inhibitors - chemistry</topic><topic>Histone Deacetylase Inhibitors - therapeutic use</topic><topic>Histone Deacetylases - metabolism</topic><topic>Humans</topic><topic>Leukemia</topic><topic>Leukemia - drug therapy</topic><topic>Leukemia - enzymology</topic><topic>Methylation</topic><topic>Physiological aspects</topic><topic>Review</topic><topic>Risk assessment</topic><topic>Rodents</topic><topic>Studies</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pession, Andrea</creatorcontrib><creatorcontrib>Biagi, Carlotta</creatorcontrib><creatorcontrib>Serravalle, Salvatore</creatorcontrib><creatorcontrib>Masetti, Riccardo</creatorcontrib><collection>قاعدة دراسات الشباب - e-Marefa Youth Studies</collection><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>قاعدة الخدمة الاجتماعية والعمل الخيري والأوقاف - e-Marefa Social & Charitable Work and Endowments</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection (ProQuest)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pession, Andrea</au><au>Biagi, Carlotta</au><au>Serravalle, Salvatore</au><au>Masetti, Riccardo</au><au>Seiser, Christian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias</atitle><jtitle>BioMed research international</jtitle><addtitle>J Biomed Biotechnol</addtitle><date>2011-01-01</date><risdate>2011</risdate><volume>2011</volume><issue>2011</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>1110-7243</issn><issn>2314-6133</issn><eissn>1110-7251</eissn><eissn>2314-6141</eissn><abstract>Acute leukemia is the most common type of childhood and adolescence cancer, characterized by clonal proliferation of variably differentiated myeloid or lymphoid precursors. Recent insights into the molecular pathogenesis of leukemia have shown that epigenetic modifications, such as deacetylation of histones and DNA methylation, play crucial roles in leukemogenesis, by transcriptional silencing of critical genes. Histone deacetylases (HDACs) are potential targets in the treatment of leukaemia, and, as a consequence, inhibitors of HDACs (HDIs) are being studied for therapeutic purposes. HDIs promote or enhance several different anticancer mechanisms, such as apoptosis, cell cycle arrest, and cellular differentiation and, therefore, are in evidence as promising treatment for children and adolescents with acute leukemia, in monotherapy or in association with other anticancer drugs. Here we review the main preclinical and clinical studies regarding the use of HDIs in treating childhood and adolescence leukemia.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Puplishing Corporation</pub><pmid>21318168</pmid><doi>10.1155/2011/148046</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1110-7243 |
| ispartof | BioMed research international, 2011-01, Vol.2011 (2011), p.1-9 |
| issn | 1110-7243 2314-6133 1110-7251 2314-6141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3026992 |
| source | MEDLINE; PubMed Central Open Access; Wiley Online Library (Open Access Collection); PubMed Central; Alma/SFX Local Collection |
| subjects | Adolescent Animals Antimitotic agents Antineoplastic agents Apoptosis Cancer Chemotherapy Child Clinical Trials as Topic Cyclin-dependent kinases DNA DNA methylation Drug Evaluation, Preclinical Drug therapy Epigenetics Health aspects Histone Deacetylase Inhibitors - chemistry Histone Deacetylase Inhibitors - therapeutic use Histone Deacetylases - metabolism Humans Leukemia Leukemia - drug therapy Leukemia - enzymology Methylation Physiological aspects Review Risk assessment Rodents Studies Tumors |
| title | The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T16%3A35%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Role%20of%20HDACs%20Inhibitors%20in%20Childhood%20and%20Adolescence%20Acute%20Leukemias&rft.jtitle=BioMed%20research%20international&rft.au=Pession,%20Andrea&rft.date=2011-01-01&rft.volume=2011&rft.issue=2011&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=1110-7243&rft.eissn=1110-7251&rft_id=info:doi/10.1155/2011/148046&rft_dat=%3Cgale_pubme%3EA266629939%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=856177672&rft_id=info:pmid/21318168&rft_galeid=A266629939&rfr_iscdi=true |